Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Committee hears case for broader insurance coverage of biomarker cancer tests
Summary
Dr. Hol told the Senate Health & Welfare Committee that biomarker testing — including circulating tumor DNA — is integral to personalized cancer care, can reduce costs by stopping unnecessary chemotherapy, and needs broader insurance coverage to be effective.
During the March 26 meeting of the Senate Health & Welfare Committee, Dr. Hol, director of the Vermont Cancer Center, urged broader insurer coverage for biomarker tests that guide targeted cancer therapies and can detect residual disease.
Dr. Hol said biomarker testing is routine in modern cancer care and provided examples: certain pancreatic cancers have BRCA mutations (she estimated about 10–15% in…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
